(BWXT) BWX Technologies - Overview
Sector: Industrials | Industry: Aerospace & Defense | Exchange: NYSE (USA) | Market Cap: 18.754m USD | Total Return: 57.3% in 12m
Avg Turnover: 213M
EPS Trend: 98.4%
Qual. Beats: 2
Rev. Trend: 98.3%
Qual. Beats: 5
Warnings
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
BWX Technologies, Inc. (BWXT) is a specialized manufacturer of nuclear components and fuel, serving both government and commercial sectors. The company is a primary supplier for the United States Naval Nuclear Propulsion Program, providing reactors and precision components for submarines and aircraft carriers. Its operations extend to the commercial power industry, medical radioisotope production, and nuclear waste storage solutions.
The business model relies heavily on high-barrier-to-entry government contracts and long-term lifecycle support services. This sector is characterized by intense regulatory oversight and specialized engineering requirements, often resulting in sole-source provider status for critical defense infrastructure. Beyond defense, BWXT leverages its technical expertise to provide structural design, robotic process development, and non-destructive examination services for nuclear power plants.
To better understand the companys valuation and growth prospects, you may wish to explore the detailed analysis available on ValueRay.
Founded in 1867 and headquartered in Lynchburg, Virginia, the company rebranded from The Babcock & Wilcox Company in 2015. It maintains a diverse portfolio that includes radiopharmaceuticals and advanced fuel assemblies for research institutions, positioning it at the intersection of national security and specialized energy infrastructure.
- U.S. Navy shipbuilding schedules and Virginia-class submarine procurement drive nuclear component revenue
- Expansion of the medical radioisotope portfolio increases high-margin commercial segment profitability
- Federal funding levels for microreactors and space nuclear propulsion influence long-term growth
- Uranium price volatility and down-blending contracts impact nuclear fuel production margins
| Net Income: 344.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.24 > 1.0 |
| NWC/Revenue: 27.90% < 20% (prev 17.68%; Δ 10.22% < -1%) |
| CFO/TA 0.12 > 3% & CFO 521.8m > Net Income 344.7m |
| Net Debt (1.50b) to EBITDA (542.7m): 2.77 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago 0.04% < -2% |
| Gross Margin: 22.63% > 18% (prev 0.24%; Δ 2.24k% > 0.5%) |
| Asset Turnover: 91.54% > 50% (prev 91.09%; Δ 0.45% > 0%) |
| Interest Coverage Ratio: 10.46 > 6 (EBITDA TTM 542.7m / Interest Expense TTM 40.9m) |
| A: 0.22 (Total Current Assets 1.62b - Total Current Liabilities 674.2m) / Total Assets 4.32b |
| B: 0.60 (Retained Earnings 2.59b / Total Assets 4.32b) |
| C: 0.12 (EBIT TTM 428.4m / Avg Total Assets 3.69b) |
| D: 0.84 (Book Value of Equity 2.56b / Total Liabilities 3.04b) |
| Altman-Z'' = 5.04 = AAA |
| DSRI: 1.01 (Receivables 998.6m/817.5m, Revenue 3.38b/2.78b) |
| GMI: 1.07 (GM 22.63% / 24.16%) |
| AQI: 1.01 (AQ_t 0.26 / AQ_t-1 0.26) |
| SGI: 1.21 (Revenue 3.38b / 2.78b) |
| TATA: -0.04 (NI 344.7m - CFO 521.8m) / TA 4.32b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 195.88 with a total of 1,276,750 shares traded.
Over the past week, the price has changed by -3.28%,
over one month by -5.74%,
over three months by -4.64% and
over the past year by +57.27%.
BWX Technologies has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy BWXT.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 239.3 | 22.2% |
P/E Trailing = 54.5867
P/E Forward = 43.8596
P/S = 5.5543
P/B = 14.5183
P/EG = 1.6728
Revenue TTM = 3.38b USD
EBIT TTM = 428.4m USD
EBITDA TTM = 542.7m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last fiscal year)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.50b USD (calculated: Debt 2.02b - CCE 515.6m)
Enterprise Value = 20.3b USD (18.8b + Debt 2.02b - CCE 515.6m)
Interest Coverage Ratio = 10.46 (Ebit TTM 428.4m / Interest Expense TTM 40.9m)
EV/FCF = 61.74x (Enterprise Value 20.3b / FCF TTM 328.1m)
FCF Yield = 1.62% (FCF TTM 328.1m / Enterprise Value 20.3b)
FCF Margin = 9.72% (FCF TTM 328.1m / Revenue TTM 3.38b)
Net Margin = 10.21% (Net Income TTM 344.7m / Revenue TTM 3.38b)
Gross Margin = 22.63% ((Revenue TTM 3.38b - Cost of Revenue TTM 2.61b) / Revenue TTM)
Gross Margin QoQ = 22.99% (prev 20.98%)
Tobins Q-Ratio = 4.68 (Enterprise Value 20.3b / Total Assets 4.32b)
Interest Expense / Debt = 2.03% (Interest Expense 40.9m / Debt 2.02b)
Taxrate = 15.03% (16.1m / 107.3m)
NOPAT = 364.0m (EBIT 428.4m * (1 - 15.03%))
Current Ratio = 2.40 (Total Current Assets 1.62b / Total Current Liabilities 674.2m)
Debt / Equity = 1.58 (Debt 2.02b / totalStockholderEquity, last quarter 1.28b)
Debt / EBITDA = 2.77 (Net Debt 1.50b / EBITDA 542.7m)
Debt / FCF = 4.58 (Net Debt 1.50b / FCF TTM 328.1m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.34% (Net Income 344.7m / Total Assets 4.32b)
RoE = 27.91% (Net Income TTM 344.7m / Total Stockholder Equity 1.23b)
RoCE = 13.17% (EBIT 428.4m / Capital Employed (Equity 1.23b + L.T.Debt 2.02b))
RoIC = 9.95% (NOPAT 364.0m / Invested Capital 3.66b)
WACC = 8.81% (E(18.8b)/V(20.8b) * Re(9.57%) + D(2.02b)/V(20.8b) * Rd(2.03%) * (1-Tc(0.15)))
Discount Rate = 9.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -15.56 | Cagr: -0.04%
[DCF] Terminal Value 76.50% ; FCFF base≈304.6m ; Y1≈349.2m ; Y5≈514.0m
[DCF] Fair Price = 61.74 (EV 7.16b - Net Debt 1.50b = Equity 5.66b / Shares 91.6m; r=8.81% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.36 | EPS CAGR: 12.79% | SUE: 2.71 | # QB: 2
Revenue Correlation: 98.27 | Revenue CAGR: 13.32% | SUE: 1.00 | # QB: 5
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=-5.48% | Revisions=-54% | Analysts=9
EPS next Quarter (2026-09-30): EPS=1.23 | Chg30d=-0.15% | Revisions=-67% | Analysts=9
EPS current Year (2026-12-31): EPS=4.71 | Chg30d=+2.14% | Revisions=+57% | GrowthEPS=+17.5% | GrowthRev=+18.5%
EPS next Year (2027-12-31): EPS=5.21 | Chg30d=+0.62% | Revisions=+27% | GrowthEPS=+10.4% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: -67%